Weight Loss Medications in 2026: GLP-1 Market Shift

Key Takeaways

• The FDA approved oral semaglutide (Wegovy) and Lilly's oral orforglipron (Foundayo) in early 2026, expanding the weight loss medications category beyond injectables.
• Evaluate Pharma projects the global obesity pharmacotherapy market at roughly $58 billion in 2026, rising above $130 billion by 2035.
• Novo Nordisk reported DKK 41.7 billion in Wegovy obesity-care sales in Q1 2026; Lilly reported incretin revenue above $8 billion in the same quarter.
• CMS finalized a Medicare Part D demonstration allowing Medicare Advantage plans to cover anti-obesity GLP-1 medications from July 2026—a U.S. payer inflection for weight loss medications access.

Oral Formulations Reshape the GLP-1 Class

Injectable semaglutide and tirzepatide established the clinical benchmark for weight loss medications, but real-world adherence limited addressable volume. The FDA's oral Wegovy approval and Lilly's Foundayo approval shift the competitive frame toward convenience and primary-care prescribing.

Novo Nordisk stated that more than 80% of early oral Wegovy prescriptions came from patients new to GLP-1 therapy—evidence that weight loss medications are expanding the treated population rather than merely switching existing injectable users. Trial registries underscore ongoing differentiation: SURMOUNT-5 (NCT05822830) compares tirzepatide head-to-head with semaglutide 2.4 mg, while OASIS 4 (NCT05564174) evaluates higher-dose oral semaglutide over 68 weeks.

In Europe, the EMA CHMP recommended oral semaglutide 25 mg for weight management, pending Commission decision—an important parallel track for multinational launch sequencing.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Revenue Concentration and Filing Evidence

SEC filings make the commercial concentration visible. Novo Nordisk's 2025 Form 20-F shows obesity-care products at roughly 42% of net sales. Lilly's 2025 10-K describes tirzepatide (Zepbound) as the fastest-growing portfolio product since its obesity launch. Together, these disclosures explain why weight loss medications have become a board-level growth pillar—not a niche metabolic line item.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

What It Means

For investors: Weight loss medications are now a duopoly growth category with oral formulations as the next volume lever. Revenue already visible in Q1 2026 filings reduces the "pipeline optionality" narrative; the debate shifts to gross-to-net, capacity, and payer mix.

For market access teams: The CMS demonstration is the most consequential U.S. policy catalyst in 2026. Plans that move early on GLP-1 coverage will shape formularies before competitors; those that wait risk losing Medicare Advantage lives in obesity-heavy markets.

For BD and competitive intelligence: This analysis differs from our regulatory roundup of new weight loss drugs—here the moat is commercial synthesis tied to filings and earnings, not label tables alone. Watch orforglipron uptake versus oral semaglutide as the first head-to-head oral battle.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

What to Watch

• July 2026: Medicare Advantage GLP-1 coverage under the CMS demo
• SURMOUNT-5 readout timing and any label/commercial implications for tirzepatide vs semaglutide
• EMA Commission decision on oral semaglutide 25 mg
• Q2 2026 earnings calls for obesity revenue guidance revisions from Novo and Lilly

Frequently Asked Questions